lipase family member NGenealiases: ARCI8 · LI4 · LIPL4 · bA186O14.3
Q-omics provides the consensus-scored LIPN profile across patient tissues and cancer cell-line models. LIPN expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LIPN is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, LIPN RNA expression shows 11,960 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight ACC, LUAD, and PAAD as cancer lineages where LIPN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIPN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIPN survival associations across molecular data types. LIPN RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIPN RNA expression–survival associations across cancer types. High LIPN expression shows unfavorable associations in ACC, LUAD, UVM and LGG, but favorable associations in KIRC and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LIPN RNA expression.
This table summarizes LIPN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LIPN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIPN shows lower tumor expression in LUAD, LUSC, BRCA and LIHC and higher tumor expression in KIRC and KIRP. The LUAD box plot shows higher LIPN RNA expression in normal versus tumor tissue (log2 FC = −1.201, t-test p < 0.001).
This table shows molecular features associated with LIPN in patient tissues and cancer cell lines. In patient samples, LIPN shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LIPN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
